Data as of Apr 17
| +0.038 / +8.05%|
The 2 analysts offering 12-month price forecasts for Boston Therapeutics Inc have a median target of 1.41, with a high estimate of 1.80 and a low estimate of 1.01. The median estimate represents a +175.49% increase from the last price of 0.51.
The current consensus among 1 polled investment analysts is to Buy stock in Boston Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.